IL293115B1 - Salts and polymorphs of cethromycin for the treatment of disease Salts and polymorphs of cethromycin - Google Patents

Salts and polymorphs of cethromycin for the treatment of disease Salts and polymorphs of cethromycin

Info

Publication number
IL293115B1
IL293115B1 IL293115A IL29311522A IL293115B1 IL 293115 B1 IL293115 B1 IL 293115B1 IL 293115 A IL293115 A IL 293115A IL 29311522 A IL29311522 A IL 29311522A IL 293115 B1 IL293115 B1 IL 293115B1
Authority
IL
Israel
Prior art keywords
compound
recited
pattern
chloride
cethromycin
Prior art date
Application number
IL293115A
Other languages
English (en)
Hebrew (he)
Other versions
IL293115A (en
Inventor
Sullivan David
Hill Amanda
WITTERING Kate
TAPPER Amy
KALUDOV Nikola
Original Assignee
Aliquantumrx Inc
Sullivan David
Hill Amanda
WITTERING Kate
TAPPER Amy
KALUDOV Nikola
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aliquantumrx Inc, Sullivan David, Hill Amanda, WITTERING Kate, TAPPER Amy, KALUDOV Nikola filed Critical Aliquantumrx Inc
Publication of IL293115A publication Critical patent/IL293115A/en
Publication of IL293115B1 publication Critical patent/IL293115B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL293115A 2019-12-02 2020-12-02 Salts and polymorphs of cethromycin for the treatment of disease Salts and polymorphs of cethromycin IL293115B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962942508P 2019-12-02 2019-12-02
PCT/US2020/062882 WO2021113357A1 (en) 2019-12-02 2020-12-02 Salts and polymorphs of cethromycin for the treatment of disease salts and polymorphs of cethromycin

Publications (2)

Publication Number Publication Date
IL293115A IL293115A (en) 2022-07-01
IL293115B1 true IL293115B1 (en) 2026-02-01

Family

ID=76091614

Family Applications (1)

Application Number Title Priority Date Filing Date
IL293115A IL293115B1 (en) 2019-12-02 2020-12-02 Salts and polymorphs of cethromycin for the treatment of disease Salts and polymorphs of cethromycin

Country Status (10)

Country Link
US (3) US11697667B2 (de)
EP (1) EP4069251A4 (de)
JP (1) JP7693669B2 (de)
KR (1) KR20220108102A (de)
CN (1) CN115003309B (de)
AU (1) AU2020395150A1 (de)
CA (1) CA3163337A1 (de)
IL (1) IL293115B1 (de)
WO (1) WO2021113357A1 (de)
ZA (1) ZA202205737B (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4069251A4 (de) 2019-12-02 2023-12-06 Aliquantumrx, Inc. Salze und polymorphe von cethromycin zur behandlung von krankheiten
WO2025174723A1 (en) * 2024-02-12 2025-08-21 Selagine Inc. Ophthalmic composition comprising cethromycin
CN121370876A (zh) * 2025-12-04 2026-01-23 中国农业科学院兰州畜牧与兽药研究所 苯酰甲硝唑在制备抗弓形虫的药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6147197A (en) * 1996-09-04 2000-11-14 Or; Yat Sun 6-O-substituted erythromycin ketolides having antibacterial activity
WO2016033023A2 (en) * 2014-08-25 2016-03-03 The Johns Hopkins University Macrolide compounds and their use in liver stage malaria and related disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA51730C2 (uk) * 1996-09-04 2002-12-16 Ебботт Лабораторіз 6-o-заміщені кетоліди з антибактеріальною активністю, спосіб їх одержання (варіанти), фармацевтична композиція та спосіб регулювання бактеріальної інфекції у ссавців
WO2002014339A1 (en) * 2000-08-14 2002-02-21 Taisho Pharmaceutical Co., Ltd. Process for producing erythromycin derivative
US20020111317A1 (en) * 2000-09-25 2002-08-15 Leonard Katz Sixteen-membered macrolide compounds
CN1569777A (zh) * 2002-05-05 2005-01-26 高秉元 一种手性源与有机药物碱的药用盐或络合物
US7384921B2 (en) * 2004-02-20 2008-06-10 Enanta Pharmaceuticals, Inc. Polymorphic forms of 6-11 bicyclic ketolide derivatives
EP1962862B1 (de) * 2005-12-19 2013-09-04 Æterna Zentaris GmbH Alkylphospholipidderivate und deren verwendung
MX361413B (es) * 2010-03-22 2018-12-05 Cempra Pharmaceuticals Inc Star Formas cristalinas de un macrólido y usos para las mismas.
CN105294791A (zh) * 2014-06-10 2016-02-03 无锡康福特药物科技有限公司 一种大环内酯类药物的超微粉体及其制备方法
WO2018067663A2 (en) 2016-10-04 2018-04-12 Biopharmati Sa Ketolides having antibacterial activity
EP4069251A4 (de) 2019-12-02 2023-12-06 Aliquantumrx, Inc. Salze und polymorphe von cethromycin zur behandlung von krankheiten

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6147197A (en) * 1996-09-04 2000-11-14 Or; Yat Sun 6-O-substituted erythromycin ketolides having antibacterial activity
WO2016033023A2 (en) * 2014-08-25 2016-03-03 The Johns Hopkins University Macrolide compounds and their use in liver stage malaria and related disease

Also Published As

Publication number Publication date
CA3163337A1 (en) 2021-06-10
US11697667B2 (en) 2023-07-11
US12391720B2 (en) 2025-08-19
KR20220108102A (ko) 2022-08-02
JP7693669B2 (ja) 2025-06-17
US20230312633A1 (en) 2023-10-05
US20210163522A1 (en) 2021-06-03
CN115003309B (zh) 2024-05-24
EP4069251A1 (de) 2022-10-12
US20250340583A1 (en) 2025-11-06
CN115003309A (zh) 2022-09-02
WO2021113357A1 (en) 2021-06-10
IL293115A (en) 2022-07-01
AU2020395150A1 (en) 2022-06-23
ZA202205737B (en) 2024-12-18
JP2023504262A (ja) 2023-02-02
EP4069251A4 (de) 2023-12-06

Similar Documents

Publication Publication Date Title
US12391720B2 (en) Salts and polymorphs of cethromycin for the treatment of disease
US20220153737A1 (en) Solid forms of a compound modulating kinases
JP4781614B2 (ja) ナフチリジンカルボン酸誘導体の塩
US11179329B2 (en) Therapeutical use of H3-ligands
JP2016511273A (ja) Ｄ−グルシトール，１−デオキシ−１−（メチルアミノ）−，１−（６−アミノ−３，５−ジフルオロピリジン−２−イル）−８−クロロ−６−フルオロ−１，４−ジヒドロ−７−（３−ヒドロキシアゼチジン−１−イル）−４−オキソ−３−キノリンカルボン酸塩の結晶型
JP2024532303A (ja) 神経炎症性障害の治療
CN102803247B (zh) 组胺h3受体拮抗剂的新颖富马酸盐
JP2000351794A (ja) エリスロマイシン誘導体
US12209078B2 (en) Crystalline forms of carbazole inhibitors of RhoGTPase for the treatment of disease
AU2017340594B2 (en) Composition comprising combination of TRH analog with arundic acid, and pharmaceutically acceptable salt of arundic acid
KR102509190B1 (ko) 트리메부틴 말레산염의 다형체 및 이의 사용방법
RU2699669C1 (ru) Новые составы N-карбамоилметил-4-фенил-2-пирролидона
CN106798743A (zh) (n‑异丙基哌嗪基)‑2‑羟基苯甲酰胺化合物在制备治疗神经退行性疾病药物中的用途
US20190382396A1 (en) Salts of bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (dlk) kinase for the treatment of disease
TW202123931A (zh) 治療發炎性腸道疾病的化合物與方法
TW202448418A (zh) 發炎性腸道疾病之治療
CN107652194B (zh) 一类用于治疗神经系统疾病的化合物
HK40100619A (zh) 一种p2x3抑制剂化合物及其盐、多晶型和用途
CN115052661A (zh) 化合物和利用其的药物
NZ752311B2 (en) Composition comprising combination of trh analog with arundic acid, and pharmaceutically acceptable salt of arundic acid
US20110245311A1 (en) Histidine Derivatives
HK1248223B (en) Solid forms of a compound modulating kinases
HK1248223A1 (en) Solid forms of a compound modulating kinases
MXPA01009306A (es) Derivados de eritromicina